Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome

Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Disease
  • Aged, 80 and over
  • Chromosome Deletion
  • Chromosomes, Human, Pair 5
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Lenalidomide
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / etiology
  • Leukemia, Myeloid / genetics*
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Point Mutation
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Thalidomide
  • JAK2 protein, human
  • Janus Kinase 2
  • Lenalidomide